Mereo BioPharma Group (NASDAQ:MREO) Upgraded by Lifesci Capital to Hold Rating

Mereo BioPharma Group (NASDAQ:MREO) was upgraded by equities research analysts at Lifesci Capital to a “hold” rating in a research note issued on Thursday,Zacks.com reports.

A number of other research analysts have also issued reports on the stock. Robert W. Baird set a $1.00 price target on shares of Mereo BioPharma Group in a research note on Monday, December 29th. BTIG Research reissued a “buy” rating and set a $1.00 price objective on shares of Mereo BioPharma Group in a report on Friday, January 16th. Cantor Fitzgerald reissued an “overweight” rating on shares of Mereo BioPharma Group in a research report on Monday, December 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Mereo BioPharma Group in a research note on Thursday, January 22nd. Finally, Wall Street Zen cut Mereo BioPharma Group from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $3.25.

Mereo BioPharma Group Stock Performance

Shares of NASDAQ MREO opened at $0.34 on Thursday. Mereo BioPharma Group has a fifty-two week low of $0.20 and a fifty-two week high of $3.05. The company has a market cap of $54.42 million, a PE ratio of -5.70 and a beta of 0.34. The business has a 50-day simple moving average of $0.44 and a two-hundred day simple moving average of $1.31.

Mereo BioPharma Group (NASDAQ:MREO) last posted its quarterly earnings data on Thursday, March 19th. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). On average, sell-side analysts predict that Mereo BioPharma Group will post -0.03 earnings per share for the current fiscal year.

Institutional Trading of Mereo BioPharma Group

Large investors have recently made changes to their positions in the business. Frazier Life Sciences Management L.P. raised its holdings in shares of Mereo BioPharma Group by 20.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 9,440,112 shares of the company’s stock worth $25,583,000 after purchasing an additional 1,620,249 shares during the last quarter. Aberdeen Group plc lifted its position in Mereo BioPharma Group by 82.9% during the third quarter. Aberdeen Group plc now owns 5,538,699 shares of the company’s stock valued at $11,410,000 after purchasing an additional 2,509,827 shares during the period. Significant Wealth Partners LLC boosted its holdings in Mereo BioPharma Group by 114.8% in the third quarter. Significant Wealth Partners LLC now owns 47,814 shares of the company’s stock valued at $98,000 after purchasing an additional 25,553 shares during the last quarter. Clear Harbor Asset Management LLC grew its position in Mereo BioPharma Group by 83.3% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 77,000 shares of the company’s stock worth $159,000 after purchasing an additional 35,000 shares during the period. Finally, Forefront Wealth Partners LLC purchased a new position in shares of Mereo BioPharma Group during the 3rd quarter valued at about $68,000. 62.83% of the stock is owned by hedge funds and other institutional investors.

More Mereo BioPharma Group News

Here are the key news stories impacting Mereo BioPharma Group this week:

• Positive Sentiment: Company updates: Mereo published full‑year 2025 results and corporate highlights and said additional data analyses from the Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta are ongoing — a potential long‑term value driver if analyses produce positive signals. Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights
• Negative Sentiment: Earnings miss: Mereo reported quarterly EPS of ($0.05), missing the consensus of ($0.01). The larger-than-expected loss likely pressured sentiment and raises near‑term funding and execution concerns for a small biotech with limited market cap. Quarterly Financial Results Press Release
• Negative Sentiment: Legal / litigation risk: Multiple plaintiff law firms have announced or publicized a securities class action covering ADS purchases from June 5, 2023 through Dec 26, 2025 and are soliciting lead plaintiffs (April 6, 2026 deadline). The proliferation of filings and solicitations (Rosen, Schall, Faruqi, Bronstein, Berger Montague, Pomerantz, DJS, etc.) increases uncertainty and could lead to costly litigation or settlements. Rosen Law Firm Notice Bronstein, Gewirtz & Grossman Notice Faruqi & Faruqi Notice

About Mereo BioPharma Group

Mereo BioPharma Group plc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for rare diseases, oncology and severe respiratory conditions. The company pursues an asset‐centric model, in which it in-licenses or acquires clinical-stage small molecules and monoclonal antibodies with established safety profiles. By concentrating resources on a select number of programs, Mereo aims to accelerate proof-of-concept studies and maximize the potential value of each therapeutic candidate.

Mereo’s pipeline includes investigational therapies for skeletal disorders, such as setrusumab (BPS-804) for osteogenesis imperfecta, and treatments for acute and chronic respiratory diseases.